Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of WTX101 in newly diagnosed adult Wilson disease
2014-001703-41Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jun 2014
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atn-224 in Wilson disease (WD), sponsored by Alexion Pharmaceuticals. Primary endpoint: Non-ceruloplasmin-bound copper levels adjusted for molybdenum plasma concentration. Started Jun 2014; status: completed.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on 2014-001703-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001703-41.